- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- February 2022
Comments
RED: Treatment of adults with locally advanced or
metastatic urothelial cancer who have previously received a platinum-containing
chemotherapy and a programmed death receptor 1 or programmed death ligand 1
inhibitor. NHSE commissioned. (Decision date - February 2022)
DNP: NICE TA797 - Enfortumab vedotin for previously treated locally advanced
or metastatic urothelial cancer (terminated appraisal). NHSE commissioned. (Decision date - July 2022)
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again